Sensys
We Work Non-stop for Human Health
- Joint Stock Company SENSYS Pharmaceutical Industry started its operations in 2021.
- In 2021, it obtained 14 drug licenses and 3 Co-Marketing licenses.
- The company, which carries out pharmaceutical R&D studies and licensing activities, provides its first product CANSAR 32 mg/25 mg Film Tablet, and some products of different treatment fields, among service range of Turkish medicine in 2022.
The goal of SENSY Pharmaceuticals, which is in cooperation with the world’s leading companies with raw materials and finished products, is to ensure that innovative product services are delivered to patients in the easiest, safest and fastest way within the framework of ethical and scientific values. The licensing procedures for many pharmaceutical products continue. It has expanded its product portfolio in this field. Our biggest goal is to be a company that has achieved significant success and services.
Sensys
Sensys R & D
The main purpose of our R&D department is to build the future of the company in such a way to support the innovation power of the SENSYS Pharmaceutical products, which is its competitive advantage; as well as to follow up the upcoming developments in the world, to produce technological and scientific projects for innovation and global competition in the field of medical products, to develop alternative technologies, to reach domestic and international markets,and, to address and develop value-added products for this.
Under the roof of the R&D Center, the work is mostly focused on new product development, existing product improvement, and meeting the targeted market needs as a basis. The R&D Center aims to provide added value to our country’s economy by creating value of its own operational efforts.
In order to make tomorrow a better day
When working we use all our capacity
Meet our team
Ola Nordmann
Customer Support
Lorem ipsum..
Ola Nordmann
Customer Support
Lorem ipsum..
Ola Nordmann
Customer Support
Lorem ipsum..